

Special Issue

Restoring Ethical and Effective Communication about Vaccination

Message from the Guest Editors

Vaccination, a topic that had long been neglected in the broader public interest, found itself in the midst of a vigorous and polarized debate during the COVID-19 pandemic. Much emphasis has been placed on particular positions and policies regarding vaccination. However, as both the masses and health professionals deal with fatigue, frustration, and challenges to their trust, it is time to reemphasize *how* we communicate, as much or more than *what* we communicate. Time is of the essence, as there is an urgent need for a range of new vaccinations—there are already warnings of a ‘triple-demic’ of COVID-19, flu, and respiratory syncytial virus this year—which may become part of 21st century life and beyond. Similarly, we must restore focus and momentum on vaccine development against globally important diseases such as malaria and viral hemorrhagic fevers. In this Special Issue, we invite data, insights, exploration, and reflection from across biomedical, social science, and humanities disciplines on this ethical imperative—to restore trust and, with it, health.

Guest Editors

Prof. Dr. Arri Eisen

Department of Biology, Institute for the Liberal Arts, Emory University,
Atlanta, GA 30322, USA

Dr. Odaro John Huckstep

United States Air Force Academy, Colorado Springs, CO 80840, USA

Deadline for manuscript submissions

closed (1 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/147331

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).